Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American collaborative retina study group at 6 months of follow-up

Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American collaborative retina study group at 6 months of follow-up

Author Wu, Lihteh Google Scholar
Arevalo, Jose Fernando Google Scholar
Roca, Jose Antonio Google Scholar
Maia, Mauricio Autor UNIFESP Google Scholar
Berrocal, Maria Hortensia Google Scholar
Rodriguez, Francisco J. Google Scholar
Evans, Teodoro Google Scholar
Costa, Rogerio Alves Autor UNIFESP Google Scholar
Cardillo, José Augusto Autor UNIFESP Google Scholar
PACORES Google Scholar
Institution Inst Cirugia Ocular
Clin Oftalmol Ctr
Clin Ricardo Palma
Universidade Federal de São Paulo (UNIFESP)
Univ Puerto Rico
Univ Rosario
Hosp Olhos Araraquara
Abstract Purpose: To report the 6-month anatomical and visual outcomes after injecting two different doses of intravitreal bevacizumab in patients with macular edema secondary to branch retinal vein occlusion (BRVO).Methods: An interventional, retrospective multicenter study of 45 eyes that were treated with at least one intravitreal injection (24 eyes, 1.25 mg; 21 eyes, 2.5 mg) of bevacizumab is reported. The main outcome measures were the central 1-mm macular thickness (CMT) and the change in ETDRS lines of best-corrected visual acuity (BCVA) at 6 months.Results: Forty-five eyes were injected on average 26.1 months (range, 3-86 months) after the diagnosis. The average follow-up was 35.2 weeks (range, 24-52 weeks). All patients completed at least 6 months of follow-up. In the 1.25-mg dose group, at 1 month, there was an average gain of 4.5 lines of BCVA; at 3 months, 5.1 lines of BCVA; and at 6 months, 5.1 lines of BCVA (P < 0.005). In the 2.5-mg dose group, at 1 month, there was an average gain of 2.3 lines of BCVA; at 3 months, 3.8 lines of BCVA; and at 6 months, 4.8 lines of BCVA (P = 0.05). In the 1.25-mg dose group, the mean CMT +/- SD decreased from 461 +/- 211 mu m at baseline to 321 +/- 152 mu m at 1 month, 273 +/- 99 mu m at 3 months, and 277 +/- 114 mu m at 6 months (P = 0.0002). In the 2.5-mg group, the mean CMT +/- SD decreased from 385 +/- 168 mu m at baseline to 279 +/- 111 mu m at 1 month, 249 +/- 97 mu m at 3 months, and 240 +/- 93 mu m at 6 months (P = 0.011).Conclusion: There were no statistically significant differences between the two dose groups with regard to the number of injections and anatomical and functional outcomes. Intravitreal injection of bevacizumab at doses up to 2.5 mg appears to be effective in improving BCVA and reducing CMT in BRVO in the short term. Multiple injections are needed in a large number of eyes for continued control of macular edema and preservation of visual acuity in the short term. Longer studies are needed to determine what role if any intravitreal injection of bevacizumab may play in the long-term treatment of this condition.
Keywords bevacizumab
branch retinal vein occlusion
macular edema
vascular endothelial growth factor
Language English
Date 2008-02-01
Published in Retina-the Journal Of Retinal And Vitreous Diseases. Philadelphia: Lippincott Williams & Wilkins, v. 28, n. 2, p. 212-219, 2008.
ISSN 0275-004X (Sherpa/Romeo, impact factor)
Publisher Lippincott Williams & Wilkins
Extent 212-219
Origin http://dx.doi.org/10.1097/IAE.0b013e3181619bee
Access rights Closed access
Type Article
Web of Science ID WOS:000253460800003
URI http://repositorio.unifesp.br/11600/45215

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account